Elizabeth Forminard's most recent trade in Johnson & Johnson was a trade of 51,688 Employee Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Feb. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 51,688 | 51,688 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,189 | 3,189 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 11,366 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 10,321 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 1,922 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 9,627 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 8,991 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 464 | 10,902 (0%) | 0% | 156.7 | 72,713 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 307 | 10,014 (0%) | 0% | 156.1 | 47,938 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 267 | 9,360 (0%) | 0% | 156.7 | 41,842 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 215 | 8,776 (0%) | 0% | 155.3 | 33,381 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,352 | 1,352 | - | - | Performance Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 46,406 | 46,406 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,883 | 2,883 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 8,576 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 236 | 8,340 (0%) | 0% | 157.9 | 37,253 | Common Stock |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,448 | 8,548 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,448 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 1,034 | 7,925 (0%) | 0% | 157.4 | 162,752 | Common Stock |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 411 | 8,959 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 979 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 979 | 6,463 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 363 | 6,100 (0%) | 0% | 156.3 | 56,748 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 32,317 | 32,317 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 2,555 | 6,408 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,953 | 1,953 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 924 | 5,484 (0%) | 0% | 162.0 | 149,697 | Common Stock |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,022 | 4,233 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,022 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 380 | 3,853 (0%) | 0% | 162.1 | 61,590 | Common Stock |